Increased Peripheral Blood Heteroplasmy of the mt.3243A>G Mutation Is Associated with Earlier End-Stage Kidney Disease: A Case Report and Review of the Literature

Nephron ◽  
2020 ◽  
Vol 144 (7) ◽  
pp. 358-362
Author(s):  
James A.D. Shand ◽  
Howard C. Potter ◽  
Helen L. Pilmore ◽  
Tim Cundy ◽  
Rinki Murphy
Keyword(s):  
Case Report ◽  
Kidney Disease ◽  
Peripheral Blood ◽  
Review Of The Literature ◽  
End Stage Kidney Disease ◽  
End Stage

scholarly journals Mild sodium reduction in peritoneal dialysis solution improves hypertension in end stage kidney disease: a case-report study

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Luigi Vecchi ◽  
Mario Bonomini ◽  
Roberto Palumbo ◽  
Arduino Arduini ◽  
Silvio Borrelli
Keyword(s):  
Blood Pressure ◽  
Peritoneal Dialysis ◽  
Case Report ◽  
Kidney Disease ◽  
Substantial Reduction ◽  
End Stage Kidney Disease ◽  
Low Sodium ◽  
First Case ◽  
End Stage ◽  
Residual Diuresis

Abstract Introduction Blood Pressure (BP) control is largely unsatisfied in End Stage Kidney Disease (ESKD) principally due to sodium retention. Peritoneal Dialysis (PD) is the most common type of home dialysis, using a peritoneal membrane to remove sodium, though sodium removal remains challenging. Methods This is a case-study reporting two consecutive ESKD patients treated by a novel peritoneal PD solution with a mildly reduced sodium content (130 mmol/L) to treat hypertension. Results In the first case, a 78-year-old woman treated by Continuous Ambulatory PD (CAPD) with standard solution (three 4 h-dwells per day 1.36% glucose 132 mmol/L) showed resistant hypertension confirmed by ambulatory blood pressure monitoring (ABPM), reporting 24 h-BP: 152/81 mmHg, day-BP:151/83 mmHg and night-ABP: 153/75 mmHg, with inversion of the circadian systolic BP rhythm (1.01), despite use of three anti-hypertensives and a diuretic at adequate doses. No sign of hypervolemia was evident. We then switched from standard PD to low-sodium solution in all daily dwells. A six-months low-sodium CAPD enabled us to reduce diurnal (134/75 mmHg) and nocturnal BP (122/67 mmHg), restoring the circadian BP rhythm, with no change in ultrafiltration or residual diuresis. Diet and drug prescription were unmodified too. The second case was a 61-year-old woman in standard CAPD (three 5 h-dwells per day) suffering from hypertension confirmed by ABPM (mean 24 h-ABP: 139/84 mmHg; mean day-ABP:144/88 mmHg and mean night-ABP:124/70 mmHg). She was switched from 132-Na CAPD to 130-Na CAPD, not changing dialysis schedule. No fluid expansion was evident. During low-sodium CAPD, antihypertensive therapy (amlodipine 10 mg and Olmesartan 20 mg) has been reduced until complete suspension. After 6 months, we repeated ABPM showing a substantial reduction in mean 24 h-ABP (117/69 mmHg), mean diurnal ABP (119/75 mmHg) and mean nocturnal ABP (111/70 mmHg). Ultrafiltration and residual diuresis remained unmodified. No side effects were reported in either cases. Conclusions This case-report study suggests that mild low-sodium CAPD might reduce BP in hypertensive ESKD patients.

scholarly journals Bardet-Biedl syndrome with end-stage kidney disease: A case report and review of literature

2007 ◽  
Vol 17 (1) ◽  
pp. 10 ◽  
Author(s):  
V Jha ◽  
M Rathi ◽  
A Ganguli ◽  
SK Singh ◽  
HS Kohli ◽  
...  
Keyword(s):  
Case Report ◽  
Kidney Disease ◽  
Review Of Literature ◽  
End Stage Kidney Disease ◽  
Bardet Biedl Syndrome ◽  
End Stage

scholarly journals Successful peritoneal dialysis for the end-stage kidney disease associated with Prader–Willi syndrome: a case report

2019 ◽  
Vol 8 (3) ◽  
pp. 216-220 ◽  
Author(s):  
Emi Anno ◽  
Keiichiro Hori ◽  
Ainori Hoshimoto ◽  
Makiko Harano ◽  
Sou Hagiwara ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Case Report ◽  
Kidney Disease ◽  
Prader Willi Syndrome ◽  
End Stage Kidney Disease ◽  
End Stage
Sign in / Sign up

Export Citation Format

Share Document